Regen BioPharma Vergangene Ertragsentwicklung
Vergangenheit Kriterienprüfungen 0/6
Regen BioPharma has been growing earnings at an average annual rate of 18.1%, while the Biotechs industry saw earnings growing at 19% annually. Revenues have been growing at an average rate of 20.8% per year.
Wichtige Informationen
18.1%
Wachstumsrate der Gewinne
37.9%
EPS-Wachstumsrate
Biotechs Wachstum der Industrie | 17.0% |
Wachstumsrate der Einnahmen | 20.8% |
Eigenkapitalrendite | n/a |
Netto-Marge | -373.1% |
Letzte Ertragsaktualisierung | 30 Jun 2024 |
Jüngste Aktualisierungen vergangener Leistungen
Keine Aktualisierungen
Recent updates
Aufschlüsselung der Einnahmen und Ausgaben
Wie Regen BioPharma Geld verdient und ausgibt. Basierend auf den neuesten gemeldeten Einnahmen der letzten zwölf Monate.
Gewinn- und Umsatzhistorie
Datum | Einnahmen | Umsatz | Allgemeine und Verwaltungskosten | F&E-Ausgaben |
---|---|---|---|---|
30 Jun 24 | 0 | -1 | 0 | 0 |
31 Mar 24 | 0 | -1 | 0 | 0 |
31 Dec 23 | 0 | -1 | 0 | 0 |
30 Sep 23 | 0 | 1 | 1 | 0 |
30 Jun 23 | 0 | 1 | 1 | 0 |
31 Mar 23 | 0 | 62 | 1 | 0 |
31 Dec 22 | 0 | 1 | 1 | 0 |
30 Sep 22 | 0 | 2 | 0 | 0 |
30 Jun 22 | 0 | 1 | 0 | 0 |
31 Mar 22 | 0 | -67 | 0 | 0 |
31 Dec 21 | 0 | -6 | 0 | 0 |
30 Sep 21 | 0 | -7 | 0 | 0 |
30 Jun 21 | 0 | -4 | 0 | 0 |
31 Mar 21 | 0 | 6 | 0 | 0 |
31 Dec 20 | 0 | 2 | 0 | 0 |
30 Sep 20 | 0 | 3 | 0 | 0 |
30 Jun 20 | 0 | 4 | 0 | 0 |
31 Mar 20 | 0 | -4 | 1 | 0 |
31 Dec 19 | 0 | 0 | 1 | 0 |
30 Sep 19 | 0 | -3 | 1 | 0 |
30 Jun 19 | 0 | -5 | 1 | 0 |
31 Mar 19 | 0 | -1 | 1 | 0 |
31 Dec 18 | 0 | -2 | 1 | 0 |
30 Sep 18 | 0 | -5 | 1 | 0 |
30 Jun 18 | 0 | -5 | 1 | 1 |
31 Mar 18 | 0 | -8 | 1 | 1 |
31 Dec 17 | 0 | -8 | 1 | 2 |
30 Sep 17 | 0 | -6 | 1 | 1 |
30 Jun 17 | 0 | -5 | 2 | 1 |
31 Mar 17 | 0 | -4 | 2 | 1 |
31 Dec 16 | 0 | -3 | 2 | 1 |
30 Sep 16 | 0 | -3 | 2 | 1 |
30 Jun 16 | 0 | -3 | 2 | 1 |
31 Mar 16 | 0 | -3 | 2 | 1 |
31 Dec 15 | 0 | -3 | 2 | 0 |
30 Sep 15 | 0 | -2 | 2 | 0 |
30 Jun 15 | 0 | -2 | 2 | 0 |
31 Mar 15 | 0 | -1 | 1 | 0 |
31 Dec 14 | 0 | -1 | 1 | 0 |
30 Sep 14 | 0 | -1 | 1 | 0 |
30 Jun 14 | 0 | -1 | 1 | 0 |
31 Mar 14 | 0 | -1 | 0 | 0 |
Qualität der Erträge: RGBP is currently unprofitable.
Wachsende Gewinnspanne: RGBP is currently unprofitable.
Analyse von freiem Cashflow und Gewinn
Analyse des Gewinnwachstums in der Vergangenheit
Ergebnisentwicklung: RGBP is unprofitable, but has reduced losses over the past 5 years at a rate of 18.1% per year.
Beschleunigtes Wachstum: Unable to compare RGBP's earnings growth over the past year to its 5-year average as it is currently unprofitable
Erträge im Vergleich zur Industrie: RGBP is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.3%).
Eigenkapitalrendite
Hohe Eigenkapitalrendite: RGBP's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.